• Tidak ada hasil yang ditemukan

1 SUPPLEMENTAL MATERIALS TABLE OF CONTENTS Page 2

N/A
N/A
Protected

Academic year: 2024

Membagikan "1 SUPPLEMENTAL MATERIALS TABLE OF CONTENTS Page 2"

Copied!
11
0
0

Teks penuh

(1)

1 SUPPLEMENTAL MATERIALS TABLE OF CONTENTS

Page 2: Supplemental Table 1: P-values for interaction by the following terms on associations between symptoms and subsequent myocardial infarction

Page 3: Supplemental Table 2: Additive interactions between absence or presence of chest pain, shortness of breath, and inability to climb stairs with Relative Excess Risk due to Interaction Page 4: Supplemental Table 3: Associations between categorical time-updated symptoms of atherosclerosis and myocardial infarction, stratified by diabetes status

Page 5: Supplemental Table 4: Associations between categorical time-updated symptoms of

atherosclerosis and myocardial infarction, additionally adjusted for changes in symptoms since the last visit (N=3909)

Page 6: Supplemental Figure 1: Incidence rate of myocardial infarction by chest pain severity and diabetes status (error bars represent the upper bounds of the 95% confidence interval)

Page 7: Supplemental Figure 2: Incidence rate of myocardial infarction by shortness of breath severity and diabetes status (error bars represent the upper bounds of the 95% confidence interval)

Page 8: Supplemental Figure 3: Incidence rate of myocardial infarction by limitation climbing stairs and diabetes status (error bars represent the upper bounds of the 95% confidence interval)

Page 9: Supplemental Figure 4: Frequency of changes in chest pain from preceding annual visit Page 10: Supplemental Figure 5: Frequency of changes in shortness of breath from preceding annual visit

Page 11: Supplemental Figure 6: Frequency of changes in difficulty climbing stairs from preceding annual visit

(2)

2

Supplemental Table 1: P-values for interaction by the following terms on associations between symptoms and subsequent myocardial infarction

Prior myocardial infarction or revascularization

eGFR (continuous)

eGFR (categorical)

Proteinuria (continuous)

Sex

Chest pain 0.18 0.92 0.97 0.85 0.13

Shortness of breath

0.69 0.46 0.70 0.15 0.10

Inability to climb stairs

0.18 0.96 0.44 0.48 0.95

Adjusted for sex, self-reported race/ethnicity, time-updated age, time-updated prior myocardial

infarction or revascularization, prior stroke, diabetes, systolic and diastolic blood pressure, heart failure, atrial fibrillation, BMI, COPD, eGFR, current smoking status, log-transformed proteinuria, use of coronary vasodilators, calcium channel blockers, and beta blockers.

(3)

3

Supplemental Table 2: Additive interactions between absence or presence of chest pain, shortness of breath, and inability to climb stairs with Relative Excess Risk due to Interaction

Symptoms Relative excess risk

due to interaction (95% CI) Chest Pain (any vs none) and Shortness of Breath (any vs none) -0.00 (-0.84, 0.83) Chest Pain (any vs none) and Inability to Climb Stairs (any vs none) -0.18 (-1.64, 1.29) Shortness of Breath (any vs none) and Inability to Climb Stairs (any vs none) -0.80 (-2.05, 0.44)

(4)

4

Supplemental Table 3: Associations between categorical time-updated symptoms of atherosclerosis and myocardial infarction, stratified by diabetes status

Hazard Ratio (95% Confidence Interval)

Adjusted, without diabetes Adjusted, with diabetes Chest Pain

No bother 1.0 (Referent) 1.0 (Referent)

Mild bother 1.51 (0.95, 2.39) 1.22 (0.91, 1.64)

Moderate or worse

bother 2.48 (1.50, 4.11) 1.46 (1.03, 2.07)

P-value for trend across

symptom severity < 0.001 0.02

Shortness of Breath

No bother 1.0 (Referent) 1.0 (Referent)

Mild bother 1.55 (1.01, 2.36) 1.3 (1.01, 1.67)

Moderate or worse

bother 2.68 (1.79, 4.03) 1.00 (0.75, 1.33)

P-value for trend across

symptom severity < 0.001 0.72

Inability to climb stairs

No limitation 1.0 (Referent) 1.0 (Referent)

Mild limitation 1.49 (0.97, 2.27) 1.43 (1.01, 2.02)

Severe limitation 1.77 (1.13, 2.77) 1.94 (1.38, 2.72)

P-value for trend across

symptom severity 0.01 < 0.001

Adjusted for sex, self-reported race/ethnicity, time-updated age, prior myocardial infarction or revascularization, prior stroke, diabetes, systolic and diastolic blood pressure, heart failure, atrial fibrillation, BMI, COPD, eGFR, current smoking status, log-transformed proteinuria, use of coronary vasodilators, calcium channel blockers, and beta blockers.

Bold font indicates statistically significant confidence interval

(5)

5

Supplemental Table 4: Associations between categorical time-updated symptoms of atherosclerosis and myocardial infarction, additionally adjusted for changes in symptoms since the last visit (N=3909)

Hazard Ratio (95% Confidence Interval)

Model 1 Model 2 Model 3 Model 4: additionally

adjusted for preceding symptoms Chest Pain

No bother 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) Mild bother 1.63 (1.28, 2.08) 1.36 (1.06, 1.74) 1.30 (1.01, 1.67) 1.37 (1.06, 1.78) Moderate or worse

bother 2.22 (1.67, 2.94) 1.80 (1.35, 2.40) 1.70 (1.27, 2.27) 1.97 (1.40, 2.76) Shortness of Breath

No bother 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) Mild bother 1.62 (1.31, 2.00) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.45 (1.16, 1.82) Moderate or worse

bother 1.80 (1.44, 2.26) 1.37 (1.08, 1.74) 1.33 (1.05, 1.69) 1.55 (1.18, 2.04) Inability to climb

stairs

No limitations 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) 1.0 (Referent) Mild limitations 1.86 (1.43, 2.43) 1.47 (1.12, 1.92) 1.44 (1.10, 1.89) 1.51 (1.15, 1.99) Severe limitations 3.00 (2.32, 3.87) 1.95 (1.48, 2.56) 1.89 (1.44, 2.49) 2.08 (1.54, 2.82) Model 1: Adjusted for sex, self-reported race/ethnicity, and time-updated age

Model 2: Adjusted for the components of Model 1 plus time-updated prior myocardial infarction or revascularization, prior stroke, diabetes, systolic and diastolic blood pressure, heart failure, atrial fibrillation, BMI, COPD, eGFR, current smoking status, and log-transformed proteinuria

Model 3: Adjusted for the components of Model 2 plus time-updated use of coronary vasodilators, calcium channel blockers, and beta blockers

Model 4: Adjusted for the components of Model 3 plus changes in symptoms from the visit preceding the analyzed visit

Bold font indicates statistically significant confidence interval

(6)

6

Error Bars represent the upper bounds of the 95% confidence interval.

(7)

7

Error Bars represent the upper bounds of the 95% confidence interval.

(8)

8

Error Bars represent the upper bounds of the 95% confidence interval.

(9)

9

(10)

10

(11)

11

Referensi

Dokumen terkait

TABLE OF CONTENTS.. PAGE OF APPROVAL

Supplemental Digital Content 1,

3 Supplemental Digital Table 2 Patterns of Interaction Between Guiding Principles and Modifiers That Emerged from Five Focus Groups of 40 Practicing Internists Discussing

Research letter: Validity of Administrative data 1 Supplemental Table 1: Definitions using information available in administrative data Definition of Outcomes Stroke primary

SUPPLEMENTAL DIGITAL CONTENT SDC Table 1... SUPPLEMENTAL DIGITAL CONTENT SDC Table

Supplemental Table 1: Assessment of steroid toxicity 1 Growth retardation: height >2 standard deviations below normal according to Tanner et al* in the absence of other causes of

Supplemental table 1 Gene Forward 5’-3’ Reverse 5’-3’ Product length bp CB1R TCTGCTTGCGATCATGGTGT GCATGTCTCAGGTCCTTGCT 147 CB2R GTCATGTGGGTCCTCTCAGC AGAAGCCAGCCCAGTAGGTA 122 GPR55

Supplemental Table 5 Characteristics of employed kidney transplant recipients of whom a WRFQ total score was available for primary analyses, of whom the WRFQ total score was set at